Contact Us Locations About Products Pipeline Partnering Patients Investors & News Careers Lucitanib Clinical Development Pipeline Overview Rucaparib FAP-2286 Lucitanib Scientific Presentations Clinical Trials Compassionate Use Lucitanib Clinical Development Overview Lucitanib, is an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). The LIO-1 Phase 2 study, evaluating lucitanib and nivolumab in gynecologic cancers is underway. Clovis has global rights for lucitanib excluding China. Lucitanib Scientific Presentations Phase 1b/2 SEASTAR Trial: Safety, Pharmacokinetics, and Preliminary Efficacy of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Rucaparib and Angiogenesis Inhibitor Lucitanib in Patients with Advanced Solid Tumors Poster Presentation 2021 ASCO Virtual Annual Meeting Download the PDF Download the Presentation Slides PDF LIO-1: Lucitanib + Nivolumab in Patients with Advanced Solid Tumors–Updated Phase 1b Results and Initial Experience in Phase 2 Ovarian Cancer Cohort (NCT04042116; ENGOT-GYN3/AGO/LIO) Poster Presentation 2021 ASCO Virtual Annual Meeting Download the PDF Download the Supplementary Material Download the Presentation Slide PDF About Pipeline Patients Investors & News Careers Contact Us Privacy Policy Cookie Policy Terms Sitemap COPYRIGHT © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. By using this website without changing your cookie settings, you agree to our use of cookies. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. By clicking Accept you consent to our use of cookies. Accept